Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1972 1
1996 1
1999 2
2001 2
2003 1
2008 3
2010 1
2011 2
2012 1
2013 2
2014 4
2015 6
2016 2
2017 1
2018 1
2019 1
2020 3
2021 5
2022 11
2023 4
2024 4
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.
Ozen A, Chongsrisawat V, Sefer AP, Kolukisa B, Jalbert JJ, Meagher KA, Brackin T, Feldman HB, Baris S, Karakoc-Aydiner E, Ergelen R, Fuss IJ, Moorman H, Suratannon N, Suphapeetiporn K, Perlee L, Harari OA, Yancopoulos GD, Lenardo MJ; Pozelimab CHAPLE Working Group. Ozen A, et al. Among authors: jalbert jj. Lancet. 2024 Feb 17;403(10427):645-656. doi: 10.1016/S0140-6736(23)02358-9. Epub 2024 Jan 23. Lancet. 2024. PMID: 38278170 Free PMC article. Clinical Trial.
Dementia of the Alzheimer type.
Jalbert JJ, Daiello LA, Lapane KL. Jalbert JJ, et al. Epidemiol Rev. 2008;30:15-34. doi: 10.1093/epirev/mxn008. Epub 2008 Jul 16. Epidemiol Rev. 2008. PMID: 18635578 Review.
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review.
von Tresckow B, Abrisqueta P, Zamanillo I, Serna Á, Kuang Y, Uyei J, Shah M, Walsh L, Thorley E, Cantos K, Rashidi E, Hampp C, Jalbert JJ, Archambault AN, Xu Y, Aggarwal S, Ambati S, Mohamed H, Ma Q, Jiménez-Ubieto A. von Tresckow B, et al. Among authors: jalbert jj. Eur J Haematol. 2025 Aug;115(2):104-116. doi: 10.1111/ejh.14423. Epub 2025 May 9. Eur J Haematol. 2025. PMID: 40344463 Free PMC article.
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review.
Abrisqueta P, Jiménez-Ubieto A, Serna Á, Zamanillo I, Kuang Y, Uyei J, Shah M, Walsh L, Thorley E, Cantos K, Rashidi E, Ma Q, Jalbert JJ, Archambault AN, Xu Y, Aggarwal S, Ambati S, Mohamed H, Hampp C, von Tresckow B. Abrisqueta P, et al. Among authors: jalbert jj. Ann Hematol. 2025 Sep;104(9):4357-4367. doi: 10.1007/s00277-025-06575-9. Epub 2025 Sep 2. Ann Hematol. 2025. PMID: 40892075 Free PMC article.
Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments.
Litcher-Kelly L, Ozen A, Ollis S, Feldman HB, Yaworsky A, Medrano P, Chongsrisawa V, Brackin T, Perlee L, Walker M, Pradeep S, Lenardo MJ, Harari OA, Jalbert JJ. Litcher-Kelly L, et al. Among authors: jalbert jj. Orphanet J Rare Dis. 2024 Aug 8;19(1):290. doi: 10.1186/s13023-024-03277-9. Orphanet J Rare Dis. 2024. PMID: 39118150 Free PMC article. Clinical Trial.
Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Silverberg JI, et al. Among authors: jalbert jj. Ann Allergy Asthma Immunol. 2021 Jan;126(1):40-45. doi: 10.1016/j.anai.2020.07.026. Epub 2020 Jul 31. Ann Allergy Asthma Immunol. 2021. PMID: 32739313 Free article.
62 results